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Abstract 
 
 
An ideal generic cancer immunotherapy should mobilize the immune system to destroy tumor 
cells without harming healthy cells and remain active in case of recurrence. Furthermore, it 
should preferably not rely on tumor-specific surface markers, as these are only available in a 
limited set of malignancies. Despite approval for treatment of various cancers, clinical 
application of cytokines is still impeded by their multiple toxic side effects. Type I interferon 
(IFN) has a long history in the treatment of cancer, but its multifaceted activity pattern and 
complex side effects prevent its clinical use. Here we develop AcTakines (Activity-on-Target 
cytokines), optimized (mutated) immunocytokines that are up to 1000-fold more potent on target 
cells, allowing specific signaling in selected cell types only. Type I IFN-derived AcTaferon-
targeting Clec9A+ dendritic cells (DC) displayed strong antitumor activity in murine melanoma, 
breast carcinoma, and lymphoma models and against human lymphoma in humanized mice 
without any detectable toxic side effects. Combined with immune checkpoint blockade, 
chemotherapy, or low-dose TNF, complete tumor regression and long-lasting tumor immunity 
were observed, still without adverse effects. Our findings indicate that DC-targeted AcTaferons 
provide a novel class of highly efficient, safe, and broad-spectrum off-the-shelf cancer 
immunotherapeutics with no need for a tumor marker. 
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Introduction 
 
Interferon-alpha (IFN-α) is a type I IFN (IFN), approved for the treatment of several neoplasms, 
including hematological (chronic myeloid leukemia and other lympho- and myeloproliferative 
neoplasms) and solid cancers (melanoma, renal cell carcinoma, Kaposi’s sarcoma) (1,2). 
Unfortunately, success of IFN therapy has been variable and unpredictable, and is severely 
limited due to side effects, such as flu-like symptoms, nausea, leukopenia, anemia, 
thrombocytopenia, hepatotoxicity, cognitive dysfunction and depression. Best antitumor results 
are associated with the highest doses of IFN, but nearly all patients treated with these high doses 
suffer from severe adverse effects, and in up to 60% of them these even warrant drastic dose 
modification (1,3). The key mechanism of IFN antitumor activity is mainly indirect, via immune 
activation (4). Several host immune cells, including dendritic cells (DC), T and B lymphocytes, 
Natural Killer (NK) cells and macrophages, all respond to IFN and may be involved in antitumor 
activity (2,5). Furthermore, endogenous IFN is essential for cancer immunosurveillance (6,7), 
and for anti-cancer therapies including chemotherapy, radiotherapy, immunotherapies and 
checkpoint inhibition (5,8-13).  
Safe exploitation of the clinical potential of IFN, and many other cytokines, requires strategies to 
direct their activity to selected target cells, avoiding systemic toxicity. In addition, identifying the 
precise cellular therapeutic target(s) of IFN will also help to design better and safer treatments, 
separating its beneficial from detrimental cell-specific effects. One strategy to accomplish this is 
by developing immunocytokines, fusions of wild type (WT) cytokines coupled to antibodies 
recognizing cell-specific surface-expressed markers. For immunocytokines in development, an 
approximately 10-fold increase in targeted activity is achieved, increasing the therapeutic index 
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modestly (14,15). Indeed, even if coupled to a targeting moiety, WT cytokines still exert 
unwanted effects while “en route” to their target, due to high affinity binding to their 
ubiquitously expressed cognate receptors. In addition, WT (immuno)cytokines may also rapidly 
disappear from the circulation before reaching their target cells (the so-called “sink effect”) (16). 
To improve the therapeutic index of toxic cytokines, we recently protein-engineered AcTakines 
(Activated by Targeting Cytokines), optimized immunocytokines that use mutated cytokines 
with strongly reduced affinity for their receptor complex instead of WT cytokines (17). Fusing 
the mutated cytokine to cell-specific targeting domains specifically targets them to the selected 
cell population, restoring the AcTakine activity at that particular cell population with an up to 3-
log targeting efficiency. In the present study, we applied this AcTakine concept for the first time 
to the field of oncology and demonstrate remarkable efficacy using Clec9A
+
 DC-targeted 
AcTaferon (mutant type I IFN) in mouse and humanized models of hematological malignancies 
and solid tumors (melanoma and carcinoma). Importantly, successful AcTaferon (AFN) therapy 
completely lacked side effects, in sharp contrast with WT IFN, even in fully tumor-eradicating 
combination therapies with checkpoint inhibiting immunotherapies, chemotherapy, or TNF. 
Hence, DC-targeted AFN therapy represents a new, safe and off-the-shelf cancer treatment, 
without the need for a tumor marker.  
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Materials and Methods 
 
Construction and production of AcTaferons and immunocytokines 
The mutation Q124R was introduced into the IFNa2 sequence by site-directed mutagenesis using 
the QuikChange II-E Site-Directed Mutagenesis Kit (Agilent Technologies) and sdAb were 
generated at the VIB Protein Service Facility, as described previously (17). AcTaferons 
(hIFN2Q124R or hIFNR149A coupled via a 20xGGS-linker to an N-terminal targeting sdAb) 
were constructed in pHen6 vectors, large scale productions of His-tagged AFNs were performed 
in E. coli. The bacteria were LacZ promoter. Cell supernatant was collected after overnight 
culture. The proteins in the periplasmic fraction were released by osmotic shock using a sucrose 
solution and were purified by immobilized metal ion chromatography (IMAC) on a HiTrap 
Sepharose resin loaded with Kobalt ions (Clontech, Takara Biotechnology). After binding of the 
protein, columns were washed with 0.5% EMPIGEN (Calbiochem, Millipore), 0.5% CHAPS 
(Sigma-Aldrich) and PBS. Imidazole (Merck) was used for elution and removed using PD-10 gel 
filtration columns (GE Healthcare). Protein concentration was determined using the absorbance 
at 280 nm and purity was assessed via SDS-PAGE. LPS levels were quantified using Limulus 
Amebocyte Lysate (LAL) QCL-1000 (Lonza). If still present, LPS was removed using 
Endotoxin Removal Resin (Thermo Scientific). Biological activities of all products were 
assessed by a functional assay using the mouse luciferase reporter cell line LL171 against the 
WHO International mouse IFNa standard Ga02-901-511 as described previously (17). 
 
Study design 
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Our objective was to develop an AcTaferon with equivalent antitumor potential as WT type I 
IFN but without the concomitant systemic toxicity. Before the start of the treatments, tumor-
bearing mice were randomly and blindly allocated to a therapy group, for the antitumor 
experiments the size of the groups was determined by the number of mice available with an 
appropriate tumor size; we strived to have at least 5 animals per experimental group. To 
determine clear-cut unambiguous antitumor effect, we know from experience that 5 animals 
suffice to obtain statistical significance. No data or outliers were excluded. Monotherapy tumor 
experiments were performed in at least 7 individual experiments, combination therapies in at 
least 2. The number of experiments and mice (n) are reported for each figure.  
 
Statistics 
Data were normally distributed, and the variance between groups was not significantly different. 
Differences in measured variables between the experimental and control group were assessed by 
using one-way or two-way ANOVA followed by Dunnett's or Tukey’s multiple-comparison test. 
Survival curves were compared using the log-rank test. GraphPad Prism software was used for 
statistical analysis. 
 
Mice, cells and murine tumor models 
Mice were maintained in pathogen–free conditions in a temperature-controlled environment with 
12/12 hour light/dark cycles and received food and water ad libitum. Female C57BL/6J and 
Balb/c mice (Charles River Laboratories, Saint-Germain sur l'Arbresle, France) were inoculated 
at the age of 7-9 weeks, except for the orthotopic 4T1 model (12 weeks). For experiments using 
knock-out mice (CD11c-IFNAR, CD4-IFNAR, Batf3), mice were bred in our own facilities and 
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WT littermates were used as controls. For s.c. tumor models, cells were injected using a 30G 
insulin syringe, in 50 l suspension, on the shaved flank of briefly sedated mice (using 4% 
isoflurane). For the s.c. B16 melanoma model 6.10
5
 cells were inoculated; for the 4T1 model 10
5
 
cells; for the A20 lymphoma model 5.10
6
 cells. The A20 cell line is a gift from Valerie Molinier-
Frenkel (INSERM, Creteil, France), the other cell lines were purchased from the American Type 
Culture Collection and cultured in conditions specified by the manufacturer. All cells used for 
inoculation were free of mycoplasma. For the orthotopic 4T1 model, mice were anaesthetized 
with a mixture of Ketamin (Nimatek, 70 mg/kg) and Xylazine (Rompun, 10 mg/kg, Bayer), the 
4
th
 mammary fat pad was surgically exposed and injected with 10
4
 4T1 cells in 10 l using a 30G 
insulin syringe. The incision was closed using 6-0 coated vicryl absorbable suture (Ethicon). For 
the humanized model, HIS mice were s.c. inoculated with 2.10
6
 human RL follicular lymphoma 
cells 13 wk after human stem cell transfer. Tumor diameters were measured using a caliper. To 
analyze tumor immunity, mice were re-challenged on the contralateral flank with a new dose of 
tumor cells. For analysis of tumor immunity in the A20 model, mice were inoculated i.v., 36 
days after the first tumor inoculation, with 10
5
 cells. 
 
Humanized Immune System (HIS) mice 
Human cord blood CD34
+
 haematopoietic stem cells (HSC) were HLA-type matched with the 
RL tumor cells used for the antitumor experiments. To that end, and prior to HSC isolation, cord 
blood samples were stained with HLA-A2-FITC (BD Pharmingen) or HLA-ABC-PE (BD 
Pharmingen), with the latter serving as a positive control. Samples were analyzed on an Attune 
Nxt Acoustic Focusing Cytometer (Life Technologies). Human cord bloods that proved to be 
HLA-A2
+
 were selected for subsequent CD34
+
 HSC purification. In short, viable mononuclear 
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cells were isolated using Fycoll (Lymphoprep, Stemcell technologies) gradient separation prior 
to CD34
+
 MACS isolation using direct CD34
+
 progenitor cell isolation kit (Miltenyi). Isolated 
cells were stained with anti-human-CD34-APC (BD Pharmingen) to evaluate purity of the 
isolated stem cells by flow cytometry; purity of injected cells reached 90-98%. To obtain mice 
with a fully humanized immune system (HIS mice), newborn NOD-scid IL2Rgamma
null
 (NSG) 
mice (1-3 days of age) were sublethally irradiated with 100 cGy prior to intrahepatic delivery of 
10
5
 HLA-A2
+
 CD34
+
 human HSCs. At 8 weeks after CD34
+
 cell transfer, peripheral blood was 
collected from all mice. Blood samples were lysed to remove red blood cells and stained with 
pan-leukocyte anti-human-CD45-BV510 (BD Pharmingen) and anti-mouse-CD45-PECy7 
(eBioscience) antibodies. Samples were acquired on a LSR flow cytometer (BD) and analyzed 
by FACS Diva software (BD) to determine the level of human immune cell engraftment. Human 
cell engraftment typically ranged from 5-20% of viable peripheral blood cells. 
 
Tumor treatments 
Unless otherwise indicated, tumor treatments were done perilesionally (p.l.), which is s.c. at the 
tumor border. As a control, mice were always treated with PBS. AFNs were given at 5,500 IU 
per treatment, WT mIFN at 5-9.106 unless noted otherwise in the figure legend. These 
treatment doses corresponded to 30 g protein (1.4 mg/kg). For combination therapies, we 
injected doxorubicine (3 mg/kg), rmTNF (28 g/kg), anti-PDL1 sdAb (5.5 mg/kg), anti-CTLA4 
Ab (450 g/kg), anti-OX40 Ab (1.8 mg/kg). In the A20 model, anti-CTLA4 Ab (45 g/kg) and 
anti-OX40 Ab (180 g/kg) were used, analogous with the doses in the reference paper (18). 
 
Inhibitors and antibodies 
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To inhibit the immune modulating PD1-PDL1 pathway, mice were treated with a neutralizing 
anti-PDL1 sdAb (120 g/mouse), given i.p. every second day. To block CTLA4 signaling and 
deplete intratumoral regulatory T cells (18), we used anti-CTLA4 (10 g/mouse, BioXCell clone 
9H10) and anti-OX40 (40 g/mouse, BioXCell clone OX-86) given 3x/week. Depletion of CD8+ 
cells was performed by i.p. administration of 200 g rat-anti-mouse CD8 Ab (BioXCell clone 
YTS169.4) one day prior to the first AFN treatment. Additional depletion rounds were 
performed 4 and 10 days after the first. Control (non-depleted) mice were treated with 200 g rat 
IgG2b Isotype Control Ab (BioXCell clone LTF-2). Depletion of CD4
+
 cells was performed by 
i.p. administration of 200 g rat-anti-mouse CD4 Ab (BioXCell, clone GK1.4) three days prior 
to the first AFN treatment. Additional depletion rounds were performed at the day of the first 
AFN treatment as well as at day 3, 6 and 10 after the first AFN treatment. CD8
+
 and CD4
+
 cell 
depletion were evaluated with flow cytometry on blood, spleen, lymph nodes and tumor, as well 
as via IHC on spleen and tumor sections. 
 
Flow cytometry analysis and sorting 
For ex vivo P-STAT1 signaling analysis, Clec9A- AFN was injected intravenously through the 
retro-orbital vein in Balb/c mice (female, 8 weeks) and spleens were recovered 45 minutes later. 
Splenocytes were isolated, fixed, permeabilized and labelled with anti-CD11c-AlexaFluor488, 
anti-CD8-APC and anti-Y701-phospho-Stat1-PE antibodies (BD Biosciences) (17). Samples 
were acquired on a FACS Canto (BD Biosciences) and data were analyzed using FlowJo 
software. For analysis of CD19
+
 B, CD4
+ 
and CD8
+
 T cell populations in circulation, blood was 
collected from the tail vein with a heparinized capillary and stained for flow cytometric analysis 
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using CD19, CD4 or CD8 antibodies (CD19 FITC, BD; CD4 APC, Immunotools; CD8 PE, 
eBioScience). 
 
Analysis of the DC activation status 
To address the impact of perilesional AFN treatment on the DC activation status in the tumor-
draining lymph node, B16 melanoma bearing mice were injected with BCII10- AFN, or Clec9A- 
AFN (5000 IU) or PBS. 24 hours post injection, tumor draining lymph nodes were dissected and 
processed for flow cytometry. Cell suspensions were stained with CD16/CD32 to block Fc-
receptors, followed by staining with CD3-Alexa Fluor700, CD19-Alexa Fluor700, Ly6C-PE-
Cy7, CD11b-APC-Cy7, CD86-eFluor450, PDL1-PE, CD40-APC, CD80-APC, CD11c-PE 
eFluor610, MHCII-FITC (all eBioscience), XCR1-BV650 (BioLegend). After exclusion of T 
and B cells and Ly6C
hi
 monocytes, DCs were identified based on their expression of CD11c and 
MHCII. XCR1
+
 cDC1s were identified based on their XCR1
+
 CD11b
-
 MHCII
int-hi 
CD11c
int-hi
 
phenotype, whereas CD11b
+
 cDC2s were identified based on their XCR1
-
 CD11b
+
 MHCII
int-hi 
CD11c
int-hi
 phenotype. Samples were acquired on a BD LSR Fortessa (5-laser) and analyzed 
using FlowJo software.    
To address chemokine upregulation by tumor-resident DC, B16-bearing mice were injected with 
PBS or Clec9A-AFN and stained with CD16/CD32 to block Fc receptors, followed by CD11c-
APC (clone N418, Biolegend). Doublets were excluded and cells were sorted based on CD11c 
expression using Beckman Coulter MoFlo® High Performance cell sorter. RNA of the sorted 
cells was isolated according to the manufacturer’s protocol using RNeasy Purification kit 
(Qiagen) and cDNA was synthesized using PrimeScript kit (Takara); qPCR on the indicated 
genes was performed using Light Cycler 480 SYBR Green Master Mix (Roche). Data were 
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normalized and quantified relative to the stable reference genes GAPDH, HPRT1 and LDHA 
with BioGazelle qBase software.  
 
Analysis of CTL influx, proliferation and activation 
To analyze tumor T cell influx and CD8/Treg ratio, tumors were dissected at different time 
points after single perilesional delivery of AFN and processed for flow cytometry. Fc-receptors 
were blocked using CD16/CD32, whereupon single cell suspensions were stained with live/dead 
marker-fixable Aqua, CD3-PeCy7 (clone 145-2C11), CD4-PE (clone RMA-5), CD8-PerCP 
(clone 53-6.7) (all BD Pharmingen), CD25-APC (clone PC61.5) and FoxP3-FITC (clone 
150D/E4) (both eBioScience). Intracytoplasmatic Foxp3 staining was performed according to the 
manufacturer’s protocol (eBioScience). Tregs were identified based on CD3+CD8-
CD4
+
CD25
+
Foxp3
+
 phenotype.  
To analyze activated T cell phenotype, mice were perilesionally injected with PBS or AFN at 
day 10 and 12 after tumor inoculation. Tumor-draining lymph nodes and tumors were dissected 
three days after the last perilesional delivery of AFN and processed for flow cytometry. Fc-
receptors were blocked using CD16/CD32, whereupon single cell suspensions were stained with 
live-dead-Fixable Aqua, CD3-PeCy7 (clone 145-2C11), CD4-PE (clone RMA-5), CD8-APC 
(clone 53-6.7) (all BD Pharmingen), CD44-PerCP-Cy5.5 (clone IMF7) and CD62L-APC-Cy7 
(clone MEL-14) (both BioLegend). Effector T cells were identified based on their 
CD44
hi
CD62L
low
 phenotype, naive T cells based on CD44
low
CD62L
hi
 phenotype. For lymph 
nodes, central memory T cells were based on CD44
hi 
CD62L
hi
 phenotype. Samples were 
acquired on an Attune NxT Acoustic Focusing Cytometer (Life Technologies) and analyzed 
using FlowJo software. To evaluate CTL proliferation, we used T cell receptor transgenic 
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CD8
+
 T cells specifically recognizing the melanocyte differentiation antigen gp100 (Pmel-1) 
present on B16 tumor cells. Gp100-specific CD8 Pmel-1 T cells were isolated from the spleens 
of C57BL/6 Pmel-1–Thy1.1 mice, using the CD8α+ T Cell Isolation Kit (Miltenyi Biotec) and 
labeled with 5 µM of CFSE (Thermo Fisher). One million of CFSE-labeled T cells were 
adoptively transferred to C57BL/6 mice inoculated with 6.10
5
 B16 melanoma cells. 
Subsequently, mice were treated with the indicated AcTakines. Six days post adoptive T cell 
transfer, tumor-draining lymph nodes and spleen were dissected and specific T cell proliferation 
was assessed by Flow Cytometry. Samples were acquired on a BD LSR Fortessa (5-laser) or on 
an Attune Nxt Acoustic Focusing Cytometer (Life Technologies) and analyzed using FlowJo 
software. 
 
Hematological analysis 
One day after the last treatment, blood was collected from the tail vein in EDTA-coated 
microvette tubes (Sarstedt), and analyzed in a Hemavet 950FS (Drew Scientific, Waterbury, 
USA) whole blood counter.  
 
Study approval 
All animal experiments followed the Federation of European Laboratory Animal Science 
Association (FELASA) guidelines and were approved by the Ethical Committee of Ghent 
University and by the Ethics Committee for Animal Research of Languedoc-Rousillon 
(00920.01) and the French Health Authorities (C34-172-36). 
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Results 
 
AcTaferon targeted to Clec9A
+
 DCs controls B16 melanoma tumor growth without 
systemic toxicity 
We started evaluating AcTaferons (AFNs) in the B16 melanoma model, which is not sensitive to 
direct IFN antiproliferative activity, and is considered a non- or low-immunogenic tumor, 
reflecting the poor immunogenicity of metastatic tumors in humans, and as such represents a 
“tougher test” for immunotherapy (19,20). In the cancer-immunity cycle, priming and activation 
of tumor-killing cytotoxic T lymphocytes (CTLs) represents a crucial step (21), for which 
activation and maturation of antigen-presenting DCs is key. A specific DC subset expressing 
Clec9A and XCR1 is essential for CTL responses in mice and men (22). This c (conventional) 
DC1 subset, also known as CD8
+
 DC in mice, displays superior cross-presentation capacities and 
requires type I IFN signaling for efficient tumor rejection (13,23,24). Clec9A is also known as 
DNGR-1, a C-type lectin receptor recognizing the actin cytoskeleton exposed on, or released by, 
necrotic cells. To target Clec9A
+
 cDC1, we developed single domain antibodies (sdAb) selective 
for mouse Clec9A, and coupled them to human IFN2 (not active on mouse cells) with a Q124R 
point mutation rendering it about 100-fold less active on mouse cells than murine (m) IFN(17) 
(Supplementary Fig. 1). Phospho-STAT1 detection as IFN signature demonstrated that in vivo 
administered Clec9A-mAFN selectively and highly proficiently activates the CD8
+
 CD11c
+
 
cDC1 population over a 2-log dose range (Supplementary Fig. 1). In the B16 model, Clec9A-
mAFN inhibited tumor growth as efficiently as WT mIFN (Fig. 1A). WT mIFN had identical 
effects whether targeted (to tumor cells using the surrogate CD20 tumor marker, or to DC using 
Clec9A) or not. Importantly, although Clec9A-mAFN and mIFN had comparable antitumor 
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effects in identical protein concentrations (Fig. 1A), there was a dramatic difference in systemic 
toxicity. While mIFN caused body weight loss, severe thrombocytopenia, anemia and 
leukopenia, Clec9A-mAFN therapy did not (Fig. 1B-H). Reduced platelet numbers combined 
with increased platelet sizes, as seen after mIFN (Fig. 1D-E), indicate platelet destruction. 
Bioactivity measurements revealed that the AFN dose used for therapy was at least 1,000-fold 
lower than mIFN. For the representative experiment (Fig. 1), doses used were 6,000,000 and 
5,500 IU for mIFN and AFN, respectively. In contrast with DC-targeted AFN, 5,500 IU mIFN 
could not prevent tumor growth (Supplementary Fig. 2). In conclusion, targeting IFN signaling 
to Clec9A
+
 DCs efficiently controls tumor growth, without the need for tumor markers. 
 
DC and CTL signaling and activation induced by DC-targeted AcTaferon delivery 
As the targeted cDC1 require Batf3 transcription factor for their differentiation, deletion of 
Batf3 ablates their development (22). Experiments in cDC1-deficient Batf3
-/-
 mice confirmed the 
absolute need for cDC1 for the antitumor efficacy of Clec9A-mAFN (Fig. 2A). Also in mice 
where type I IFN signaling is absent in cDC only (CD11c-IFNAR
-/-
) (24), Clec9A-mAFN could 
not prevent tumor growth (Fig. 2B). CD8
+
 CTL are considered the most important cells to 
control tumor growth by killing cancer cells. They get selectively activated to recognize tumor 
cells by cDC1 cross-presenting tumor antigen. Indeed, depletion of CD8
+
 cells abolished 
Clec9A-mAFN antitumor efficacy (Fig. 2C). Interestingly, although the helper function of CD4
+
 
T cells can improve the proficiency of tumor-reactive CD8
+
 CTLs, depletion of CD4
+
 cells did 
not affect the antitumor efficacy of Clec9A-mAFN (Fig. 2D). In contrast to CD11c-IFNAR
-/- 
(Fig. 2B), Clec9A-mAFN could still prevent tumor growth in mice lacking IFN signaling in T 
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cells (CD4-IFNAR
-/-
), attesting the need for Clec9A-mAFN signaling in DC rather than T 
lymphocytes (Fig. 2E). 
To evaluate DC activation, we analyzed different populations isolated from tumor-draining 
lymph nodes after treatment with Clec9A-targeted or untargeted mAFN, for which we used the 
sdAb targeting BcII10, an epitope absent in the mouse (confirmed by imaging) (25). While 
BcII10-mAFN had a moderate effect on XCR1
+
 cDC1 activation marker expression, Clec9A-
mAFN was clearly superior (Fig. 3A). For the Clec9A-negative CD11b
+
 cDC2, untargeted and 
Clec9A-targeted mAFN had comparable effects (Fig. 3B). Similar effects were seen in non-
tumor-draining lymph nodes. 
As already mentioned, CD8
+
 CTLs play a key role in controlling tumor growth by actively 
killing the tumor cells. Also in Clec9A-mAFN therapy, CD8
+
 effector T cells are essential for 
successful antitumor results (Fig. 2C). Corroborating the CD8
+
 T lymphocyte activation status, 
treatment with Clec9A-mAFN significantly reduced the amount of naive T lymphocytes 
(expressing low levels of CD44 and high levels of CD62L) (Fig. 3C), increased the number of 
activated CD8
+
 effector and central memory T cells (Fig. 3D-E), and amplified tumor-antigen-
specific CTL proliferation (Fig. 3F) in tumor-draining lymph nodes. 
To analyze the effect of AcTaferon treatment on intratumoral DC and T lymphocytes, we first 
evaluated the numbers of CD3
+
, CD8
+
 or CD4
+
 cells at different time points ranging from 4 
hours till 5 days after a single treatment with Clec9A-mAFN. However, we could not find any 
significant differences with PBS treated animals. Even when CD8/regulatory T cells (Treg) 
ratios were determined, no significant changes could be detected (Fig. 4A). However, the 
activation status of the CD8
+ 
CTL present inside the tumor changed significantly (Fig. 4B-C). In 
addition, analysis of data from The Cancer Genome Atlas (TCGA) from several human tumor 
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types identified a very strong prognostic value, for outcome across several human cancers, for 
cDC1 abundance, stronger even than total T cell abundance or CTL/macrophage ratios (26). 
Tumor-residing cDC1 were recently identified to be required for efficient CTL attraction into the 
tumor by means of their production of critical chemokines such as CXCL9 and CXCL10 (27). 
Also in TGCA data on human metastatic melanoma, the cDC1 score was shown to be strongly 
correlated with expression of the latter chemokines, as well as with the presence of activated 
CTL (27). Isolating DCs from tumors to evaluate chemokine expression levels indicated higher 
DC numbers in Clec9A-mAFN treated tumors, and correlated with increased chemokine 
transcription levels (Fig. 4 D-F).  
 
Clec9A-AcTaferon represents a generic antitumor drug without systemic toxicity 
Since our strategy does not involve a tumor marker, we next evaluated the generic nature of 
Clec9A-mAFN in the entirely different 4T1 mammary carcinoma model in Balb/c mice. Clec9A-
mAFN inhibited 4T1 growth, implanted subcutaneously or orthotopically (Fig. 5A-B), without 
toxicity (Supplementary Fig. 3). Of note, Clec9A-mAFN also reduced the prominent 
neutrophilia typically associated with breast carcinoma tumors such as 4T1 (Supplementary 
Fig. 3) that may be linked to metastatic potential (28,29). 
Recently, remarkable antitumor efficacy was shown in A20-lymphoma-bearing mice treated with 
TLR9 agonist CpG in combination with Treg-depleting antibodies (18). When combined with 
Treg depletion, 100,000 IU of mIFN elicited a full antitumor response (Fig. 5C), indicating that 
the CpG activity described (18) can be recapitulated with IFN. Remarkably, treatment with a low 
dose of Clec9A-mAFN (1 g100 IU) efficiently eradicated tumors in combination with Treg-
depleting antibodies (Fig. 5D), in sharp contrast with 100 IU mIFN (Fig. 5C). 
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To translate our findings to a human situation, we developed human AFN using hIFN2 with an 
R149A mutation (17) coupled to human Clec9A-targeting sdAb, and evaluated its efficacy in 
HIS (Humanized Immune System) mice, immune-deficient animals transplanted with a human 
hematopoietic population (30). We inoculated both HIS and normal NSG mice with RL, a human 
non-Hodgkin B cell lymphoma. We intentionally chose the RL cell line which, in sharp contrast 
to other lymphoblastoid tumor cell lines such as Daudi, Raji and Namalwa, is refractory to direct 
antiproliferative effects of type I IFN. In HIS mice, hClec9A-R149A prevented tumor growth 
(Fig. 5E), but not in normal NSG mice (Fig. 5F), confirming that the antitumor potential was not 
due to direct anti-proliferative effects on the tumor cells themselves but depended on the 
reconstituted human immune system. 
 
Complete and safe tumor eradication by DC-targeted AcTaferon in combination 
treatments  
The cancer-immunity cycle indicates the sequential involvement of several steps for complete 
tumor eradication (21). Given these multiple events, plus the fact that many immune-suppressive 
mechanisms are present and may even be induced by immune-activating therapies such as IFN, 
there is a growing consensus that combination therapies will be key for successful 
immunotherapy (2,31). First, we examined whether immunogenic chemotherapy could enhance 
Clec9A-mAFN therapy. Used in a non-curative dose, doxorubicin synergized with Clec9A-
mAFN to eradicate B16 tumors (Fig. 6A).  
To facilitate tumor penetration of immune cells involved in tumor eradication, we next combined 
mIFN or Clec9A-mAFN with Tumor Necrosis Factor (TNF), known to permeabilize 
endothelium in preclinical models and isolated limb perfusion (32,33). Low-dose TNF, without 
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antitumor effect as such, strongly synergized with Clec9A-mAFN to fully destroy B16 tumors 
(Fig. 6B).  
Immune checkpoint blockade is increasingly used for several malignancies. Anti-CTLA4 and 
anti-PD1 treatments were first approved for advanced metastatic melanoma and show long-term 
cure in up to 40% of patients (34). However, clinical response and long-term benefit seem to be 
correlated to mutational load (35,36) and the majority of patients are still either resistant to 
mono-immunotherapy, or they relapse (13). Moreover, many patients suffer severe adverse 
effects, especially when treatments are combined (37). Recently, endogenous IFN was shown to 
be involved in immune checkpoint blockade efficacy (11-13,38). Anti-PDL1 sdAb therapy added 
to the tumor stasis effect of Clec9A-mAFN in the B16 tumor model (Fig. 6C).  
Also in the 4T1 breast carcinoma model, doxorubicin or TNF enhanced the antitumor efficacy of 
Clec9A-mAFN (Fig. 6D, E). While anti-PDL1 sdAb therapy added to the effect of Clec9A-
mAFN in the B16 tumor model (Fig. 6C), it did not in the 4T1 model (Fig. 6F). To escape CTL-
killing during anti-PDL1 treatment, tumor-infiltrating or –resident lymphocytes upregulate 
CTLA4 expression, and vice versa (39,40). Therefore, we added anti-CTLA4 and anti-OX40, 
depleting intratumoral regulatory T cells (41), to our anti-PDL1 regime. This resulted in tumor 
shrinkage in all mice, with 40% entirely tumor-free after only a week-long treatment (Fig. 6C, 
F). While anti-CTLA4 + anti-OX40 slowed tumor growth, anti-PDL1 as a monotherapy had no 
effect (Fig. 6C, F).  
Combined with mIFN, doxorubicin or TNF dramatically amplified toxicity resulting in extreme 
weight loss and 100% mortality (Supplementary Fig. 4). In contrast, Clec9A-mAFN plus 
doxorubicin or TNF completely destroyed B16 tumors without toxicity or mortality 
(Supplementary Fig. 4). Likewise, adding anti-PDL1, anti-CTLA-4 and/or anti-OX40 to 
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Clec9A-mAFN therapy did not cause any extra toxicity (Supplementary Fig. 5). Also in the 
4T1 tumor models, addition of doxorubicin, TNF or checkpoint blockade treatments did not 
increase toxic side effects (Supplementary Fig. 6, 7). 
 
 
AcTaferon treatment provides long-lasting tumor immunity 
As combination therapies can completely eradicate tumors, we evaluated whether therapy 
induced memory/immunity. AFN treatment lasted till 16-17 days after tumor inoculation. If 
successfully treated mice were still tumor-free on day 30-35, they were re-challenged on the 
contralateral flank. While control mice rapidly developed a B16 tumor, 60% of AFN-treated 
tumor-free mice did not develop a new tumor in the next 2 months (Fig. 7A). In the A20 
lymphoma model, all mice cured of their s.c. tumor by treatment with mIFN or Clec9A-mAFN 
combined with Treg-depleting antibodies (Fig. 5C, D) were resistant to an intravenous re-
challenge with A20 cells (Fig. 7B).  
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Discussion  
 
IFN-based cancer therapy is hampered by its yin yang character, whereby direct and/or indirect 
immune-mediated antitumor potential are offset by severe adverse side effects (1-3) and by 
IFN’s potential to suppress anti-cancer immunity (13). AcTaferons (AFNs), targeting IFN 
activity to selected cell types, can preclude toxic systemic effects and also have the potential to 
segregate the positive from detrimental qualities of IFN. We here demonstrate these clear 
advantages in preclinical models for cancer. For DC targeting, we chose Clec9A, present on the 
XCR1
+
 cross-presenting cDC1 population in mice and men (42). Treatment with Clec9A
+
 DC-
targeted AFN drastically reduced tumor growth without any sign of systemic toxicity. Strong 
antitumor effects were obtained in murine melanoma, breast carcinoma and lymphoma models, 
as well as using human AFN in a lymphoma model in humanized mice, indicating the broad 
application range and translational potential. In addition, re-challenging tumor-free mice with 
new tumors indicated a long-term memory response.  
Antitumor efficacy of Clec9A-mAFN critically depended on the presence of cDC1 and CD8
+
 
lymphocytes, and on Clec9A-mAFN signaling in cDC but not in T lymphocytes. Clec9A-mAFN 
treatment significantly increased cDC1 and T cell activation status in lymph nodes and in 
tumors. In lymph nodes, T cell proliferation was increased as well. Inside the tumors, DC were 
more numerous, but no difference in T cell numbers could be detected. Recent TCGA data 
analysis already indicated very strong prognostic value for cDC1 “high” tumors for survival 
across multiple human tumor types, suggesting that these rare cDC1 should be considered a 
target as well as a biomarker to identify checkpoint blockade responders (26). Combining AFN 
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therapy with immune checkpoint inhibition, chemotherapy, or low-dose TNF could completely 
eradicate tumors, again without causing any adverse effects, in contrast with WT IFN therapy. 
The probable reason for these synergies may be found in the cancer-immunity cycle, as 
introduced by Chen and Mellman (21), where the sequential and necessary involvement of 
several steps for complete tumor eradication also indicates several possibilities for synergistic 
therapies. These include the induction of immunogenic cancer cell death necessary for the 
release of tumor antigens (which doxorubicine is known to promote (43)), the increased antigen 
presentation capacities of DC (shaped by both type I IFN and TNF), improved priming and 
activation of T lymphocytes (positively influenced by immune checkpoint inhibiting antibodies), 
enhanced infiltration of T cells and other immune cells into the tumor mass (where TNF can play 
an important permeabilizing role (32,33)) and last but not least the actual killing of the cancer 
cells (again promoted by blocking checkpoint inhibiting signals).  
After decades of fruitless immunotherapy attempts, recent years revealed that checkpoint 
inhibition works for melanoma, lung cancer and several other tumor types (44,45). Nevertheless, 
many non-immunogenic tumors are still resistant to immunotherapy, and even in the melanoma 
population less than half of the patients are responsive. On top, about a quarter of the responsive 
patients develop resistance (13). Modulation of the tumor microenvironment to convert non-
immunogenic tumors into responders will be key to the further optimization of checkpoint 
inhibition therapy (10,13,38,44,46). Type I IFN or TLR9 agonist therapy have been suggested to 
turn “cold” tumors into immunotherapy-susceptible “hot” tumors (44,47). Our results indicate 
that Clec9A-AFN may sensitize non-immunogenic cancers in a safe and entirely non-toxic way.  
DC-targeted AFN therapy represents a DC-based immunotherapy with off-the-shelf application 
potential for various different neoplasms without the need for a tumor marker. Recent 
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developments and successes in immunotherapy include several cell-based strategies. Genetic 
modification of T cells with a chimeric antigen receptor (CAR) is the most commonly used 
approach to generate tumor specific T cells. While CAR-T cells were successful in clinical trials 
treating hematological malignancies (48), the potential of CARs in solid tumors is greatly 
hampered by the lack of unique tumor-associated antigens, inefficient homing to tumor sites and 
the immunosuppressive microenvironment of solid tumors (49). In addition, on-target/off-tumor 
effects cause severe life-threatening toxicities, evidenced by the recent unfortunate suspension of 
a phase II clinical trial (50). DC-based cancer immunotherapy has been explored since 1990 (51). 
Cultured DCs loaded with antigens in vitro boost immunity when given to patients, but the 
clinical efficiency of this approach has been limited so far. Most studies use DCs cultured from 
patients’ monocytes in vitro, requiring extensive manipulation. Ex vivo activation of different DC 
subsets obtained from the patient has also been explored, but is very laborious and expensive. 
Ideally, treatments should directly activate the patient's DCs in vivo, allowing off-the-shelf bulk 
production of a generic therapy (52). Our results using three different murine models, as well as 
a human tumor model using humanized mice, indicate that Clec9A-AFN may represent such a 
broad-spectrum, off-the-shelf therapy. Furthermore, in contrast with other proposed therapies, 
DC-targeted AFN combines DC activation and T cell recruitment and responses, without relying 
on tumor-specific surface markers (53). 
Interestingly, treatment with WT mIFN could only prevent tumor growth when used in large 
doses, and was accompanied by life-threatening toxic side effects. When used in low doses 
equivalent to the safe and effective Clec9A-mAFN therapy (5,500 IU), WT mIFN did not have 
any antitumor effect, suggesting the superiority of AFN pharmacokinetics over WT mIFN. Since 
the AFN affinity for IFNAR is seriously reduced, AFN do not bind their ubiquitously expressed 
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receptor, and hence cannot be cleared from the circulation before reaching their desired target 
cell population, a phenomenon referred to as the “sink” effect (16). 
In summary, we propose that Clec9A
+
 DC-targeted AFN represents an improved and completely 
safe IFN-based immunotherapeutic. As an antitumor treatment, DC-targeted AFN was as 
efficient as WT IFN, but without its associated toxicities. Furthermore, combination strategies 
could completely eradicate several different tumor types, and provide long-term immunity, all 
without toxicity. Importantly, DC-targeted AFN strategies do not rely on tumor-specific antigens 
at all, nor do they involve patient-specific, intricate and laborious ex vivo manipulations. As 
such, DC-targeted AFNs represent a generic and safe off-the-shelf addition to the growing 
arsenal of tumor immunotherapeutics.  
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Figure Legends 
 
Figure 1. Targeted delivery of AcTaferon to Clec9A
+
 DCs prevents B16 tumor growth (A) 
Growth of s.c. inoculated B16 tumors in C57BL/6J mice after 8 treatments (d8-12, 14, 16-17) 
with PBS, mIFN, cDC1-targeted Clec9A-AFN, or untargeted AFN (n=5 or 6 mice per group, 
shown is a representative experiment). (B) Body weight changes of tumor-bearing mice treated 
with PBS, WT mIFN or Clec9A-AFN (n=5). (C-H) Hematological analyses (red blood cells, 
platelet counts, mean platelet volume, neutrophil, monocyte and lymphocyte counts) in fresh 
EDTA-blood collected 1 day after the last treatment. All values depicted are mean ± s.e.m.; 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared with PBS treated animals; by 
two-way ANOVA with Dunnett’s multiple comparison test (A,B), or one-way ANOVA with 
Dunnett’s multiple comparison test (C-H). 
 
Figure 2. Targeted delivery of AcTaferon to Clec9A
+
 DCs depends on cDC1 and CD8 T 
cells, but IFN signaling in cDC only  (A) Growth of s.c. inoculated B16 tumors in Batf3
-/-
 mice 
(lacking cDC1) and WT littermates after 7 treatments with PBS or Clec9A-AFN (n=8 or 9 mice 
per group). (B) Growth of s.c. inoculated B16 tumors in CD11c-IFNAR-deficient mice (lacking 
IFNAR in cDC1 and cDC2) and WT littermates after 6 treatments with PBS or Clec9A-AFN 
(n=4 mice per group). (C) Growth of s.c. inoculated B16 tumors in CD8-depleted mice and 
controls after 6 treatments with PBS or Clec9A-AFN (n=6 mice per group). (D) Growth of s.c. 
inoculated B16 tumors in CD4-depleted mice and controls after 8 treatments with PBS or 
Clec9A-AFN (n=6 mice per group). (E) Growth of s.c. inoculated B16 tumors in CD4-IFNAR-
deficient mice (lacking IFNAR in all T lymphocytes) and WT littermates after 6 treatments with 
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PBS or Clec9A-AFN (n=4 mice per group). Results shown are a representative of two 
independent repeats. Shown are mean ± s.e.m. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001 compared with PBS treated animals unless otherwise indicated; determined by 
two-way ANOVA with Dunnett’s multiple comparison test. 
 
Figure 3. DC and CTL responses during DC-targeted AcTaferon treatments  (A,B) Flow 
cytometric profiling of the DC activation status in the tumor draining lymph node in response to 
AcTaferon treatment. DCs were identified as CD3
-
 CD19
-
 Ly6C
- 
CD11c
int-hi 
MHCII
int-hi 
cells and 
subdivided into XCR1
+ 
cDC1 (A) and CD11b
+
 cDC2 (B). Expression levels of PDL1, MHCII, 
CD80, CD86 and CD40 are displayed as MFI in the respective fluorescence channels. Results 
shown are a representative of two independent repeats (n=5). (C-E) Flow cytometric analysis of 
CD3
+
 CD8
+
 T cell phenotype based on the expression of CD44 and CD62L was performed on 
tumor draining lymph nodes of mice bearing B16 tumors, five days after perilesional delivery of 
the AFNs indicated in the figure legend (n=3). Naive cells (C) were identified as CD44 low and 
CD62L high, effector T cells (D) as CD44 high and CD62L low and central memory T cells as 
CD44 high and CD62L high (E). (F) Flow cytometric analysis of Pmel-1 T cell proliferation in 
the tumor draining lymph node in response to perilesional AFN treatment of B16 tumor-bearing 
mice. Data show the percentage of T cells having undergone at least one division. Shown are 
mean ± s.e.m. (A-F) as well as individual values (A, B, F); *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001 compared with PBS treated animals unless otherwise indicated; determined by 
one-way ANOVA with Tukey’s multiple comparison test. 
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Figure 4. Presence and activation state of T cells, and chemokine production by DC, in 
tumors in response to DC-targeted AcTaferon treatment  (A) Ratio of CTL vs regulatory T 
cells present in the tumor after PBS or 14h or 60h after Clec9A-AFN treatment. (B-C) Flow 
cytometric analysis of CD3
+
 CD8
+
 T cell phenotype based on the expression of CD44 and 
CD62L in B16 tumors, three days after 2 perilesional deliveries of PBS or Clec9A-AFN (n=10). 
Naive cells (B) were identified as CD44 low and CD62L high, effector T cells (C) as CD44 high 
and CD62L low. Values depicted are mean ± s.e.m.; ****P<0.0001 compared with PBS treated 
animals by two-tailed Student t test. (D-F) In vivo upregulation of CXCL9, CXCL10 and 
CXCL11 by tumor-resident DC following perilesional delivery of Clec9A-AFN or PBS. CD11c
+
 
cells were sorted from 4 pooled B16 tumors injected with PBS or Clec9A-AFN 14h before 
isolation and 10 days after tumor inoculation; qPCR was performed on cDNA synthesized from 
RNA isolated from the sorted CD11c
+
 tumor-resident cells. Shown are mean ± s.e.m. of 4 
technical replicates. 
 
Figure 5. Generic nature of Clec9A-mAFN: preventing 4T1, A20 and human RL tumor 
growth. Growth of s.c. (A) or orthotopically transplanted (B) 4T1 tumors in Balb/c mice after 8 
treatments with PBS or cDC1-targeted Clec9A-AFN (n=6 mice per group). (C, D) Balb/c mice 
were s.c. inoculated with 5.10
6
 A20 lymphoma cells. On days 11, 13 and 15, mice were treated 
intra-tumorally with PBS, 100,000 IU or 100 IU WT mIFN, or 100 IU Clec9A-AFN, combined 
with anti-CTLA4 and anti-OX40 antibodies (Abs) at days 11 and 15 (n=6 mice per group). (e) 
Newborn NSG mice (1-2 days of age) were sublethally irradiated with 100 cGy prior to 
intrahepatic delivery of 10
5
 CD34
+
 human stem cells (from HLA-A2 positive cord bloods). At 
week 13 after stem cell transfer mice were s.c. inoculated with 25.10
5
 human RL follicular 
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lymphoma cells. Mice were treated i.p. daily with 30 μg of Flt3L protein, starting at day 4 after 
tumor inoculation. Daily perilesional injection with PBS or Clec9A-hAFN (30 μg) was started at 
day 11 after tumor inoculation, when a palpable tumor was visible (n=8 mice per group). The 
antitumor effect induced by Clec9A-AFN treatment was completely absent in non-humanized 
NSG mice (F). All values depicted are mean ± s.e.m.; *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001 compared with PBS treated animals by two-way ANOVA with Dunnett’s 
multiple comparison test. 
 
Figure 6. Targeted delivery of AcTaferon to Clec9A
+
 DCs: synergies Growth of s.c. 
inoculated B16 tumors in C57BL/6J mice after 8 treatments with PBS or Clec9A-AFN (shown 
are pooled data from up to 4 experiments), combined with dox(orubicin) (A,D), low-dose TNF 
(B,E) or checkpoint inhibition (anti-PDL1 sdAb alone or combined with anti-CTLA4 + anti-
OX40) (C,F). Dividend/divisor in the figures indicates the number of tumor-free mice over the 
number of total mice at the day the experiment was ended, indicated in the X axis. Error bars 
represent mean ± s.e.m.; **P<0.01, ***P<0.001 and ****P<0.0001 compared with PBS treated 
animals by two-way ANOVA with Dunnett’s multiple comparison test.  
 
Figure 7. Clec9A-AcTaferon provides long-lasting immunity (A) Growth of B16 tumors in 
naive mice, or inoculated on the contralateral flank on day 30-35 in mice where complete 
eradication of the primary tumor was achieved thanks to Clec9A-mAFN based treatments (day 
7-17) (n=6 for naive mice, n=10 for tumor-cured mice). Tumor growth was evaluated for 60 days 
after the second tumor inoculation. (B) Mice cured from a primary s.c. A20 tumor by treatment 
with either 10
5
 IU WT mIFN or 100 IU Clec9A-mAFN were injected i.v. with 10
5
 A20 cells. A 
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control group of naive Balb/c mice was also inoculated i.v. (n=6). Graphs show Kaplan-Meier 
plots; **P<0.01, ***P<0.001, compared with naive mice by Log-rank test. 
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